LLY

992.2

+2.54%↑

JNJ

225.55

+0.2%↑

ABBV

206.52

-0.05%↓

UNH

361.4

-2.18%↓

AZN

184.31

+1.95%↑

LLY

992.2

+2.54%↑

JNJ

225.55

+0.2%↑

ABBV

206.52

-0.05%↓

UNH

361.4

-2.18%↓

AZN

184.31

+1.95%↑

LLY

992.2

+2.54%↑

JNJ

225.55

+0.2%↑

ABBV

206.52

-0.05%↓

UNH

361.4

-2.18%↓

AZN

184.31

+1.95%↑

LLY

992.2

+2.54%↑

JNJ

225.55

+0.2%↑

ABBV

206.52

-0.05%↓

UNH

361.4

-2.18%↓

AZN

184.31

+1.95%↑

LLY

992.2

+2.54%↑

JNJ

225.55

+0.2%↑

ABBV

206.52

-0.05%↓

UNH

361.4

-2.18%↓

AZN

184.31

+1.95%↑

Начало・Списък с акции・Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc

Затворен

СекторЗдравеопазване

469.14 1.68

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

459.78

Максимум

468.84

Ключови измерители
By Trading Economics
Приходи	-314M 1.7B
Продажби	-1.2B 11B
P/E Средно за сектора	25.772 49.8
EPS	5.44
Дивидентна доходност	0.38
Марж на печалбата	15.048
Служители	125,000
EBITDA	-905M 2.3B

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+34.17% upside

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	0.38% 2.25%
Следващи печалби	22.07.2026 г.
Следваща дата на дивидент	14.07.2026 г.
Следваща дата на екс-дивидент	12.06.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-24B 172B
Предишно отваряне	467.46
Предишно затваряне	469.14

Настроения в новините

By Acuity

24%

76%

85 / 347 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

406.5 / 417.79 Подкрепа & съпротива

Thermo Fisher Scientific Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

23.04.2026 г., 13:56 ч. UTC

Печалби

Thermo Fisher Profit Up, Warns of Inflation from Iran War -- Update

23.04.2026 г., 10:28 ч. UTC

Печалби

Thermo Fisher Posts Higher 1Q Profit, Revenue

29.01.2026 г., 11:34 ч. UTC

Печалби

Thermo Fisher 4Q Profit Rises as Biopharma Spending Rebounds

29.10.2025 г., 10:51 ч. UTC

Придобивния, сливания и поглъщания

Thermo Fisher Scientific Agrees to Buy Clario Holdings for $8.88 billion

23.10.2025 г., 20:49 ч. UTC

Печалби

Correction to Thermo Fisher Article on Oct. 22

22.10.2025 г., 10:28 ч. UTC

Печалби

Thermo Fisher 3Q Revenue Rises, Boosted by Life Sciences Business

23.04.2026 г., 10:01 ч. UTC

Печалби

Thermo Fisher 1Q Organic Revenue Rose 1% >TMO

23.04.2026 г., 10:01 ч. UTC

Печалби

Thermo Fisher: Well Positioned to Deliver Strong Year >TMO

23.04.2026 г., 10:00 ч. UTC

Печалби

Thermo Fisher 1Q Net $1.65B >TMO

23.04.2026 г., 10:00 ч. UTC

Печалби

Thermo Fisher 1Q Adj EPS $5.44 >TMO

23.04.2026 г., 10:00 ч. UTC

Печалби

Thermo Fisher 1Q EPS $4.43 >TMO

23.04.2026 г., 10:00 ч. UTC

Печалби

Thermo Fisher 1Q Rev $11.01B >TMO

24.03.2026 г., 12:04 ч. UTC

Придобивния, сливания и поглъщания

Thermo Fisher Completes Acquisition of Clario Holdings for $8.875 Billion >TMO

24.03.2026 г., 12:00 ч. UTC

Придобивния, сливания и поглъщания

Thermo Fisher Scientific Completes Acquisition Of Clario Holdings, Inc. >TMO

29.01.2026 г., 11:01 ч. UTC

Печалби

Thermo Fisher 4Q Organic Revenue Rose 3% >TMO

29.01.2026 г., 11:00 ч. UTC

Печалби

Thermo Fisher: Entering 2026 From Position of Strength >TMO

29.01.2026 г., 11:00 ч. UTC

Печалби

Thermo Fisher 4Q Net $1.96B >TMO

29.01.2026 г., 11:00 ч. UTC

Печалби

Thermo Fisher 4Q Rev $12.22B >TMO

29.01.2026 г., 11:00 ч. UTC

Печалби

Thermo Fisher 4Q EPS $5.21 >TMO

29.01.2026 г., 11:00 ч. UTC

Печалби

Thermo Fisher 4Q Adj EPS $6.57 >TMO

29.10.2025 г., 10:06 ч. UTC

Придобивния, сливания и поглъщания

Thermo Fisher: Clario Provides Endpoint Data Solutions for Clinical Trials >TMO

29.10.2025 г., 10:05 ч. UTC

Придобивния, сливания и поглъщания

Thermo Fisher: Claro Deal Includes Potential Additional Earnout, Other Payments >TMO

29.10.2025 г., 10:05 ч. UTC

Придобивния, сливания и поглъщания

Thermo Fisher to Buy Clario From Group Led by Astorg and Nordic Cap, Novo Holding, Cinven >TMO

29.10.2025 г., 10:04 ч. UTC

Придобивния, сливания и поглъщания

Thermo Fisher Scientific to Pay $8.875 Billion at Closing for Clario Holdings >TMO

29.10.2025 г., 10:00 ч. UTC

Придобивния, сливания и поглъщания

Thermo Fisher Scientific to Acquire Clario Holdings >TMO

22.10.2025 г., 10:01 ч. UTC

Печалби

Thermo Fisher 3Q Organic Revenue Rose 3% >TMO

22.10.2025 г., 10:00 ч. UTC

Печалби

Thermo Fisher: In Great Position to Deliver on 2025 Objectives >TMO

22.10.2025 г., 10:00 ч. UTC

Печалби

Thermo Fisher 3Q Adj EPS $5.79 >TMO

22.10.2025 г., 10:00 ч. UTC

Печалби

Thermo Fisher 3Q Rev $11.12B >TMO

22.10.2025 г., 10:00 ч. UTC

Печалби

Thermo Fisher 3Q Net $1.62B >TMO

Сравнение с други в отрасъла

Ценова промяна

Thermo Fisher Scientific Inc Прогноза

Ценова цел

By TipRanks

34.17% нагоре

12-месечна прогноза

Среден 620.69 USD 34.17%

Висок 685 USD

Нисък 560 USD

Според 15 анализатори от Wall Street, предложили 12-месечна ценова цел за Thermo Fisher Scientific Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

15 ratings

Купи

Задържане

Продай

Според 15 анализатори, дали борсови рейтинги на Thermo Fisher Scientific Inc през последните 3 месеца.

Техническа оценка

By Trading Central

406.5 / 417.79Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

All events are bearish.

Настроение

By Acuity

85 / 347 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. It has a collaboration agreement with Mainz Biomed N.V. for the development of colorectal cancer screening product. Thermo Fisher Scientific Inc. was founded in 1956 and is headquar